PreviousEntry : {EEA618B2-5639-4BA3-8F29-99B0452ACE46} | Display Title : Biosimilars Market Survey Brings Insight to Most Important Containment and Support Service Needs
NextEntry : {A39EAB56-4144-4397-B88A-E0C5BD8E7ED3} | Display Title : Addressing the Challenges in Research for Biologics
Sources

1 Jing-fen Jin, Ling-ling Zhu, Meng Chen, Hui-min Xu, Hua-fen Wang, Xiu-qin Feng, Xiu-ping Zhu, and Quan Zhou; The Optimal Choice of Medication Administration Route Regarding Intravenous, Intramuscular, and Subcutaneous Injection; Patient Preference and Adherence 9: 923-942 (2015)

2 Glynda Reese and Jodie Anita McCutcheon; Clinical Procedures for Safer Patient Care, British Columbia Institute of Technology, (2015)

3 PharmaCircle.com, Pipeline & Products Intelligence, indication-oncology, Accessed 08Dec2020

4 Dominique Leveque; Subcutaneous Administration of Anticancer Agents, Anticancer Research 34: 1579-1586 (2014)

5 Pierachille Santus, Matteo Ferrando, Ilaria Baiardini, Dejan Radovanovic, Alice Fattori, Fulvio Braido; Patients Beliefs on Intravenous and Subcutaneous Routes of Administration of Biologics for Severe Asthma Treatment: A Cross-sectional Observation al Survey Study; World Allergy Organization Journal 12 100030 (2019)

6 Melissa L. Johnson, Fadi Braiteh, Juneko E. Grilley-Olson, Jeffery Chou, Jasmine Davda, Alison Forgie, Ruifeng LI, Ira Jacobs, Farhad Kazazi, Siwen Hu-Lieskovan; Assement of Subcutaneous vs Intravenous Administration of Anti-PD-1 Antibody PF-06801591 in Patients With Advanced Solid Tumors A Phase 1 Dose-Escalation Trial; Jama Oncology 5(7) 999-1007 (2019)

7 Wolfgang F. Richter, Suraj G. Bhansali, and Marilyn E. Morris; Mechanistic Determinant or Biotherapeutics Absorption Following SC Administration; The AAPS Journal, Vol. 14, No. 3 (2012)

Previous Next
Aaron Chapman

Aaron Chapman, PhD

Program Manager, Commercial Technology Development

Subscribe to receive the latest blog post